☆ 4.2 Article

The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors

EXPERT OPINION ON PHARMACOTHERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Pharmacology & Pharmacy

Looking deeper into the findings of DARE-19: Failure or an open door to future success?

Theocharis Koufakis et al.

PHARMACOLOGICAL RESEARCH (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

Hang-Long Li et al.

Summary: This study found that SGLT2 inhibitors can reduce the risk of patients developing atrial fibrillation, embolic stroke, atrial fibrillation/flutter, and ventricular tachycardia. The associations were consistent across different baseline conditions and types of SGLT2 inhibitors used.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin

Koenraad Philippaert et al.

Summary: SGLT2 inhibitors have cardioprotective effects against heart failure by inhibiting the late component of the cardiac sodium channel current.

CIRCULATION (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes

Jin Joo Park

Summary: Diabetes increases the risk of cardiovascular disease by affecting vascular homeostasis and myocardial function. Prognosis is worse in heart failure patients with diabetes compared to those without diabetes.

DIABETES & METABOLISM JOURNAL (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?

Theocharis Koufakis et al.

Summary: Sotagliflozin, as a dual sodium-glucose co-transporter 2 inhibitor, has shown significant cardiovascular protection in heart failure patients and glucose-lowering effects.

DRUGS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

James P. Curtain et al.

Summary: The study aimed to examine the effect of dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with HFrEF. The analysis found that dapagliflozin reduced the risk of serious ventricular arrhythmias, cardiac arrest, or sudden death in these patients compared to placebo.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia

Mohammed Ali Azam et al.

Summary: The study found that EMPA treatment can reduce ventricular arrhythmia vulnerability, improve cardiac contractile function, and enhance calcium cycling and mitochondrial redox through SGLT2-independent mechanisms in a global ischemia-reperfusion model.

LIFE SCIENCES (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart

Yu Jin Chung et al.

Summary: Research indicates that cardiac NHE1 activity is not inhibited by EMPA (or other SGLT2i's) and EMPA has no effect on [Na+] over a wide range of concentrations, including the therapeutic dose.

CARDIOVASCULAR RESEARCH (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure

Nikole J. Byrne et al.

CIRCULATION-HEART FAILURE (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?

Theocharis Koufakis et al.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

Wataru Shimizu et al.

CARDIOVASCULAR DIABETOLOGY (2020)

添加到收藏夹

Editorial Material Endocrinology & Metabolism

Interpreting the results of theVERTIS-CVtrial: Is this the end of the class effect perspective?

Theocharis Koufakis et al.

JOURNAL OF DIABETES (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

Alex Ali Sayour et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

SGLT1 inhibition: Pros and cons

Vasilis Tsimihodimos et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

Laween Uthman et al.

DIABETOLOGIA (2018)

添加到收藏夹

Article Medicine, General & Internal

Declining Risk of Sudden Death in Heart Failure

Li Shen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

What causes sudden death in heart failure?

GF Tomaselli et al.

CIRCULATION RESEARCH (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.